NueHealth, GeneNews agree to three-year deal to improve screening for colorectal, lung, prostate cancer

NueHealth, a healthcare services manager, and GeneNews, an advanced diagnostics firm, agreed to a three-year partnership to offer patients access to early screening for colorectal, lung and prostate cancer.

Patients who are enrolled in NueHelath’s network now have access to three different types of cancer screening tests: ColonSentry for colorectal cancer, EARLYCDT-Lung for lung cancer and Prostate Health Index prostate cancer. These tests can be administered at any NueHealth facility and are sent to a GeneNews lab for testing.   

"Healthcare providers are increasingly being held accountable for their commitment to disease prevention and quality of care," said James Howard-Tripp, Chairman & CEO, GeneNews. "This new, integrated healthcare model is well-aligned with our risk stratification testing, which fills a key void in cancer screening, leading to improved patient adherence, reduced industry costs and better use of healthcare resources."

The combination of NueHealth’s online platforms and focus on offering cost effective and high quality care fit together with GeneNews’s services on personalized care. Working together will offer patients early detection of these three types of cancers

"One of our key drivers at NueHealth is to empower patients—we want them to take control of their health and assume a proactive role when it comes to choosing care," said Dan Tasset, Chairman of NueHealth. "Partnering with companies like GeneNews and offering innovative services like early cancer risk screenings are vital to giving patients the tools they need to stay healthy, and at the same time we're driving down the overarching costs of care, not just for patients but for providers and employers, too. It's our goal to make healthcare simple, affordable, and more accessible, and we believe partnering with GeneNews will help us do that."